Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. (DCPH) Revenue
Annual & quarterly revenue history · segment & region breakdown
DCPH · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsDeciphera Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.17B, an increase of 21.87% year-over-year from $0.16B in FY2023.
Revenue trend
2023 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.16B | +$0.03B | +21.87% |
| 2022-12-31 | $0.13B | +$0.04B | +39.41% |
| 2021-12-31 | $0.10B | +$0.05B | +128.45% |
| 2020-12-31 | $0.04B | +$0.02B | +68.35% |
| 2019-12-31 | $0.03B | +$0.03B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | — | — |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare DCPH revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Deciphera Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Deciphera Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Deciphera Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DCPH revenue · 4 questionsDCPH's trailing twelve-month (TTM) revenue is $0.17B. That is an increase of 21.87% year-over-year from $0.16B in FY2023.
▸ Source: FMP · Deciphera Pharmaceuticals, Inc. SEC filings · GAAP · Deciphera Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026